Biotechnology
-
NTRA Stock: Impressive Growth and Rising Profit Margins
Natera's impressive Q3 2024 highlights its strong position in the genetic testing market.
-
Global Fungal Outbreaks Surge
Fungal outbreaks are increasing globally, impacting health systems and creating new investment opportunities in antifungal research and treatments.
-
BMY Breaking New Ground in Schizophrenia Treatment
Bristol Myers Squibb's Cobenfy, the first new schizophrenia treatment in over 70 years, offers hope for patients and investment potential for the...
-
Viridian Therapeutics: A Biotech Tapping High-Growth Potential
See how Viridian Therapeutics (NASDAQ: VRDN) is innovating thyroid eye disease treatments with advanced therapies and a growing market opportunity.
-
Billion-Dollar Market Potential for Targeted Cancer Therapies
Radiopharmaceuticals are revolutionizing cancer treatment, attracting billions in investments. Discover the potential and challenges for investors...
-
Roche Shares Tumble After Obesity Drug Data
Roche's stock dropped 4.5% due to gastrointestinal side effects from its obesity drug CT-388, raising concerns among investors about the drug's...
-
Integra LifeSciences Implements Quality Compliance Plan
Integra LifeSciences' commitment to quality compliance and supply chain resilience may yield growth opportunities for retail investors' portfolios.
-
Viking Therapeutics Accelerates Weight Loss Drug Development
Viking Therapeutics' fast-tracked weight loss injection could reshape the market, impacting investors' portfolios and strategies.
-
Biogen Tops Q1 Estimates with Alzheimer's Boost
Dive into Biogen's impressive Q1 earnings, featuring an EPS beat and significant LEQEMBI sales growth. Explore what these results mean for the...
-
Contineum Therapeutics Raises $110 Million in Successful IPO
Contineum Therapeutics' IPO success reflects investor confidence in their innovative therapies for neuroscience, inflammation, and immunology.
-
Johnson & Johnson (JNJ) Acquires Shockwave Medical (SWAV) for $13.1B
J&J acquires Shockwave Medical for $13.1B, bolstering its medical device portfolio and positioning retail investors for potential growth in the...
-
Carl Icahn Ends Second Proxy Fight with Illumina (ILMN) Board
Activist investor Carl Icahn spares Illumina a second proxy contest, but continues lawsuit, leaving retail investors curious about board dynamics...
-
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
Toronto, ON – February 21, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...
-
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Designation Based on Pre-clinical Data and Initial Clinical Data from the Company’s MAvERIC-Pilot Phase II Study
-
Biopharmaceutical M&A Surge Revitalizes Industry
Uncover the latest M&A trends in biopharma, featuring big moves by BMY, MRK, BSX, and JNJ in a market ripe with opportunity.
-
Eli Lilly's Zepbound Shows Short-Lived Weight Loss Benefits
Uncover key investment insights in the dynamic obesity drug market. Discover growth, value, and momentum strategies in this evolving healthcare...
